Harit K. Bhatt, M.D., M.B.A, F.A.C.S., FASRS, University Retina & Macular Associates
University Retina and Macular Associates
Harit K. Bhatt, M.D., M.B.A., F.A.C.S, FASRS., is a board-certified ophthalmologist and vitreoretinal surgeon. He specializes in the medical and surgical diseases of the retina, vitreous, macula and uveitis. He also is a part of the clinical faculty at the University of Illinois at Chicago. He is expertly trained and skilled in the management of complex vitreoretinal and uveitic diseases. Dr. Bhatt utilizes the latest technology in the management of age-related macular degeneration, retinal vascular occlusions, diabetic retinopathy, retinal detachment surgery, macular hole surgery, diabetic surgery, and epiretinal membrane surgery. He is also one of the few retina specialists worldwide trained to use the NAVILAS computer-navigated retinal imaging and laser treatment system.
Dr. Bhatt has been centered in the Chicago-land area since his early childhood. He graduated from Bishop McNamara High School in Kankakee, Illinois and received his undergraduate degree with Honors in Biology at the University of Illinois at Chicago. During his undergraduate training, he was a member of the Honors College, Phi Beta Kappa Honors Society, and one of only twenty-five University Scholar Award recipients in his entire class. Dr. Bhatt received his medical degree from the University of Illinois at Chicago. After a medical internship at MacNeal Hospital in Berwyn, Illinois he completed his ophthalmology residency at the Illinois Eye and Ear Infirmary where he served as Chief Resident. Following his residency, he completed a two-year medical retina and vitreoretinal surgery fellowship at Northwestern University where he served as Chief Fellow.
In addition to his own training, Dr. Bhatt has been dedicated to educating medical students, residents, fellows and new physicians. He participates in the education curriculum at numerous Chicago-land hospitals, such as Advocate Christ Medical Center. Additionally, he is committed to clinical research and participates in clinical trials involving new medications, drug-delivery devices, and surgical instruments. Dr. Bhatt has authored and collaborated on several peer-reviewed publications, meeting lectures, and textbook chapters. He is also co-author of the new edition of the Massachusetts Eye & Ear Review Manual for Ophthalmology. Additionally, Dr. Bhatt is an active member of the American Academy of Ophthalmology and American Society of Retina Specialists. Dr. Bhatt is Board-Certified by the American Board of Ophthalmology.
Dr. Bhatt sees patients in Bedford Park, Illinois. He is on the medical staff at Advocate Christ Medical Center in Oak Lawn, Illinois, and at Advocate South Suburban in Hazel Crest, Illinois. Dr. Bhatt is fluent in English, Spanish, and Gujarati.
Vitreoretinal Fellowship
- Northwestern University Medical School
Ophthalmology Residency
- University of Illinois at Chicago, Illinois Eye and Ear Infirmary
Medical School
- University of Illinois at Chicago
Business School
- Northwestern Kellogg School of Management
Undergraduate
- University of Illinois at Chicago, Biology
Awards and Publications
Publications
Sheth V, Marcet M, Chiranand P, Bhatt HK, Lamkin JC, Jager RD. The Massachusetts Eye and Ear Infirmary Review Manual for Ophthalmology, Fourth Edition. Baltimore: Lippincott, Williams & Wilkins, 2011.
Maria Lozano-Vazquez, M.D., Jose Garcia-Gonzalez, M.D., Veeral Sheth, M.D., F.A.C.S., Harit Bhatt, M.D., F.A.C.S., Sundeep Grandhe, M.D., Madhu Amara, M.D., Rama D. Jager, M.D., M.B.A., F.A.C.S. Complications of Intravitreal Injections. IN V. Alfaro, E. Jablon, J. Kerrison, K. Sharpe, and M. Rodriguez- Fontal: Age-Related Macular Degeneration. Wolters Kluwer/ Lippincott Williams & Wilkins
Bhatt HK. Outpatient Surgical Specialities. IN Sheth V: Shelf-life Pediatrics. Wolters Kluwer/ Lippincott Williams & Wilkins
Presentations
Bhagat D, Kirby B, Bhatt HK, Jager RD, Sheth VS. Evaluating patient preferences when receiving intravitreal injections for retinal disease: A conjoint analysis. ASRS poster presentation, 2019.
Agrawal KK, Jager RD, Bhatt HK, Sheth VS. Combination therapy of intravitreal bevacizumab and focal NAVILAS laser in the treatment of macular edema due to branch retinal vein occlusion. American Society of Retinal Specialist poster presentation, 2012.
Sarah Scroggins. October 25, 2013. Beware of colored contact lenses. https://www.ahchealthenews.com
Vince Pierri. September 4, 2013. Can sleep apnea cause glaucoma? https://www.ahchealthenews.com
Health enews staff. July 17,2013. Does everyone need to be screened for glaucoma. https://www.ahchealthenews.com
Vince Pierri. July 16, 2013. Do you have computer vision syndrome? https://www.ahchealthenews.com
Vince Pierri, May 29, 2013. Are you at risk for age-related macular degeneration? https://www.ahchealthenews.com
Sarah Scroggins. November 13, 2013. Protecting eyes from screen time. https://www.ahchealthenews.com
Vince Pierri. July 11, 2013. Women need a sharp focus on eye health, experts say. https://www.ahchealthenews.com
Abstracts
VBS 2015
Headache after macular hole repair. ARVO 2015:
Visual and Anatomic Outcomes of Combined Focal Navigated Laser Photocoagulation and Intravitreal Anti-Vascular Endothelial Growth Factor for Diabetic Macular Edema
Visual and Anatomic Outcomes of Focal Navigated Laser Photocoagulation for Diabetic Macular Edema at 12 months
ASRS 2015:
Efficacy of Intravitreal Bevacizumab in Eyes with Myopic Choroidal Neovascularization Without Intraretinal or Subretinal Fluid on Spectral-domain OC
Ocular Emergencies. Advocate Christ Hospital Grand Rounds. 2010-2011. Office-Based Ophthalmology. Advocate Christ Hospital Grand Rounds. 2010-2011.
Aggrawal K, Jager R, Bhatt H, Sheth V. Combination therapy of intravitreal Bevacizumab and focal NAVILAS laser in the treatment of macular edema due to branch retinal vein occlusion. ASRS 2012.
Bhatt HK, Lyon A. Oxygen Treatment of Macula-off Retinal Detachments. Northwestern University Alumni Day. 2010.
Bhatt HK, Lyon A. Pediatric Retinal Detachments. Northwestern University Pediatric Eye Conference. 2010.
Reck P, Bhatt HK, Shapiro MJ. Outcomes of Pediatric Open Globes. ARVO 2008.
Reck P, Bhatt HK, Shapiro MJ. Pediatric Open Globes. Annual Pediatric Retina Conference University of Illinois at Chicago 2007
Chicago, IL
Blair NP, Bhatt HK, Buerk BM, Sharma MC. Traumatic Open Globe Injuries: Characteristics of Older Patients with Open Globes.
Presented at Universtiy of Illinois Alumni Day.
Bhatt HK. Pneumocephalus after Macular Hole Repair. Rabb Retina Study Club 2006-2011 Chicago, IL
Blair NP, Sharma MC, Bhatt HK, Buerk BM. Traumatic Open Globe Injuries: Characteristics of Older versus Younger Patients. ARVO 2004
Sharma MC, Bhatt HK, Buerk MB, Blair NP, McDonald TB, Fine BA, Gunnerson HB. Drug Screening in Patients with Open Globe Injury. ARVO 2004.
Other
Research
Sub-Investigator (2022-Present)
GR43828: A Phase I, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7446603 Alone and Co-Administered with Aflibercept in Patients with Diabetic Macular Edema. Sponsor: Genentech
Sub-Investigator (2022-Present)
D-4517-002: A Two Stage Phase 2 Study: Subcutaneous Dose Assessment of Safety and Pharmacodynamic Response to D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor) in subjects with Neovascular (wet) Age-Related Macular Degeneration (AMD) or subjects with Diabetic Macular Edema (DME). Sponsor: Ashvattha
Sub-Investigator (2022-Present)
Protocol CSOK583A12304: An open-label, single-arm, multicenter study in patients with nAMD to evaluate the safety of SOK583A1 (40 mg/mL), a proposed aflibercept biosimilar product, provided in a prefilled syringe. Sponsor: Sandoz
Sub-Investigator (2022-Present)
Protocol CSOK583A12303: An open-label, single-arm, multicenter study in patients with nAMD to evaluate the safety of SOK583A1 (40 mg/mL), a proposed aflibercept biosimilar product, provided in a vial kit. Sponsor: Sandoz
Sub-Investigator (2022-Present)
4D-150-C001: A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular (Wet) Age-Related Macular Degeneration. Sponsor: 4DMT
Sub-Investigator (2022-Present)
BlueTail: A Multi-Center, Non-Randomized, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200394 Following Administration in Patients with nAMD. Sponsor: Genentech
Sub-Investigator (2022-Present)
Shore Study (OPT-302-1004): A Phase 3, Multicenter, Double-Masked, Randomized Study to Evaluate the Efficacy and Safety of OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with nAMD. Sponsor: Opthea
Sub-Investigator (2022-Present)
Atmosphere (RGX-314-2104): A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD. Sponsor: RegenXBio
Sub-Investigator (2022-Present)
EYP-1901-204 (PAVIA): A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), compared to Sham for the Improvement of Moderately Severe to Severe (NPDR). Sponsor: Eyepoint
Sub-Investigator (2022-Present)
Elevatum (ML43435): A Phase IIIB/IV, Multicenter, Open-Label, Single0Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naïve, Underrepresented patients with Diabetic Macular Edema. Sponsor: Genentech
Sub-Investigator (2022-Present)
OTT-166-02 (DREAM): OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle- Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR). Sponsor: OcuTerra
Sub-Investigator (2022-Present)
Altitude (RGX-314-2202): A Phase 2, Randomized, Dose-Escalation, Observation- controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via a Single Suprachoroidal Space (SCS) Injection in Participants with DR without CI-DME. Sponsor: RegenXBio
Sub-Investigator (2022-Present)
0101 Nab Study (RGX-310-0101): Serum Anti-AAV8 Neutralizing Antibody Assessment Study of Patients with Neovascular Age-related Macular Degeneration or Diabetic Retinopathy. Sponsor: RegenXBio
Sub-Investigator (2022-Present)
Kalahari (THR-149-002): A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic macular oedema (DME). Sponsor: Oxurion
Sub-Investigator (2021-Present)
Integral Study: THR-687-002, A phase 2, randomized, multicenter study to assess the dose- level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic macular edema. Sponsor: Oxurion
Sub-Investigator (2021-Present)
Altimeter Study: MR41926, An exploratory, prospective, multi-center, open-label, single- arm, interventional, Phase IIB study to investigate aqueous humor and multimodal imaging biomarkers in treatment-naïve patients with diabetic macular edema treated with faricimab. Sponsor: Genentech/Roche
Sub-Investigator (2021-Present)
CSOK583A12301, A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety, and immunogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascular age-related macular degeneration. Sponsor: Sandoz
Sub-Investigator (2021-Present)
Balaton Study: GR41984, A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to branch retinal vein occlusion. Sponsor: Genentech/Roche
Sub-Investigator (2021-Present)
Comino Study: GR41986, A phase III, multicenter, randomized, double-masked, active comparator- controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion. Sponsor: Genentech/Roche
Sub-Investigator (2021-Present)
Capri Study: AKST4290-231, A double-masked, placebo-controlled study to evaluate the efficacy of oral AKST4290 in participants with moderately severe to severe diabetic retinopathy. Sponsor: Alkahest
Sub-Investigator (2021-Present)
PEP Study: MR41928, Patient Experience and Preference (PEP) Study in nAMD and DME. Sponsor: Genentech/Roche
Sub-Investigator (2021-Present)
GR42163, A Phase Ia, multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of RO7303359 in patients with geographic atrophy secondary to age-related macular degeneration. Sponsor: Genentech/Roche
Sub-Investigator (2021-Present)
Pulsar Study: 20968, A randomized, double-masked, active-controlled, phase 3 study of the efficacy and safety of high dose aflibercept in patients with neovascular age-related macular degeneration. Sponsor: Regeneron
Sub-Investigator (2021-Present)
Horizon Study: GT005-03, A Phase II, open-label, outcomes-assessor masked, multicenter, randomized, controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to dry age-related macular degeneration. Sponsor: Gyroscope
Sub-Investigator (2021-2022)
COOL-3 Study: A randomized, masked, controlled trial studying the use of rapid cooling anesthesia as local anesthesia for patients receiving intravitreal injections. Sponsor: Recens Medical
Sub-Investigator (2021-Present)
New Day Study: A randomized, double-masked controlled study of Intravitreal ILUVIEN implant as a baseline therapy in patients with diabetic macular edema (DME). Sponsor: Alimera
Sub-Investigator (2021-Present)
Avonelle X Study: GR42691, A multicenter, open-label extension study to evaluate the long- term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration. Sponsor: Genentech/Roche
Sub-Investigator (2021-Present)
Rhone X Study: GR41987, A multicenter, open-label extension study to evaluate the long- term safety and tolerability of faricimab in patients with diabetic macular edema. Sponsor: Genentech/Roche
Sub-Investigator (2021)
Gather 2 Study: A phase 3 multicenter, randomized, double-masked, sham-controlled clinical trial to assess the safety and efficacy pf intravitreal administration of Zimura (complement C5 inhibitor) in patients with geographic atrophy secondary to age-related macular degeneration. Sponsor: Iveric Bio
Sub-Investigator (2020-2021)
Pavilion Study: GR41675, A phase III, multicenter, randomized study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with diabetic retinopathy. Sponsor: Genentech/Roche
Sub-Investigator (2020-Present)
Portal Study: GR40549, A multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration. Sponsor: Genentech/Roche
Sub-Investigator (2020-Present)
Photon Study: VGFTe-HD-DME-1934, A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema. Sponsor: Regeneron
Sub-Investigator (2020-Present)
SCD411-CP101, SamChunDang, A phase III randomized, double-masked, parallel group, multicenter study to compare the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity between SCD411 and Eylea in subjects with neovascular age-related macular degeneration. Sponsor: SamChunDang
Sub-Investigator (2020-2021)
Canberra Study: BP41231, A randomized, double-masked, 48-week, parallel-group, placebo- controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with diabetes mellitus Type 2 pr type 2 with treatment-naïve diabetic retinopathy. Sponsor: Genentech/Roche
Sub-Investigator (2020-2021)
Candela Study: VGFTe(HD)-AMD-1905, A randomized, single-masked, active-controlled phase 2 study of the safety, tolerability, and efficacy of repeated doses of high-dose aflibercept in patients with neovascular age-related macular degeneration. Sponsor: Regeneron
Sub-Investigator (2019-Present)
Pagoda Study: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active- comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema. Sponsor: Genentech/Roche
Sub-Investigator (2019-2022)
Norse Study: A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration. Sponsor: Outlook Therapeutics
Sub-Investigator (2019-Present)
A Prospective Study of Episcleral Brachytherapy for the Treatment of Neovascular Age- related Macular Degeneration. Sponsor: Salutaris Medical Devices
Sub-Investigator (2019-2022)
Gallego Study: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Sponsor: Genentech/Roche
Sub-Investigator (2019-2021)
Altissimo: A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study). Sponsor: Graybug Vision
Sub-Investigator (2019-2021)
GTSCOPE: A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration. Sponsor: Gyroscope Therapeutics
Sub-Investigator (2019-Present)
Golden Study: A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD). Sponsor: Ionis Pharmaceuticals
Sub-Investigator (2019-2021)
Kingfisher Study: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients with Visual Impairment Due to Diabetic Macular Edema. Sponsor: Novartis
Sub-Investigator (2019-2021)
Lucerne Study: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration. Sponsor: Genentech/Roche Achievement: Top 10 in recruitment globally.
Sub-Investigator (2018-2021)
Archway Study: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active- Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration. Sponsor: Genentech/Roche
Sub-Investigator (2018-2021)
Rhine Study: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator- Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema. Sponsor: Genentech/Roche
Achievement: #1 in Global Recruitment
Sub-Investigator (2018-2021)
Panda 1: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age- related Macular Degeneration. Sponsor: Chengdu Kanghong
Sub-Investigator (2018-2019)
Topaz: Phase 3, multicenter, randomized, masked, controlled, parallel group study of suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO vs. IVT anti-VEGF agent used alone. Sponsor: Clearside Biomedical
Sub-Investigator (2017-2018)
X82-OPH-201, A randomized, double-masked, placebo-controlled, dose-finding, non- inferiority study of X-82 plus prn AVT anti-vegf monotherapy in neovascular AMD. Sponsor: Tyrogenex
Sub-Investigator (2017-2018)
AKB-9778, Phase 2 double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneous administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy. Sponsor: Aerpio
Sub-Investigator (2016-2020)
Cedar: A phase 3, multicenter, study of abicipar pegol in patients with neovascular age- related macular degeneration. Sponsor: Allergan
Sub-Investigator (2016-2019)
Panorama: A phase 3, double-masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe nonproliferative diabetic retinopathy. Sponsor: Regeneron
Sub-Investigator (2016-2018)
Boulevard: A multiple center, multiple dose, randomized, active comparator controlled, double-masked, parallel group, 24-week study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravtireally in patients with diabetic macular edema. Sponsor: Genentech/Roche
Sub-Investigator (2016-2018)
Chroma: A phase 3, multicenter, randomized double-masked sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration. Sponsor: Genentech/Roche
Sub-Investigator (2015-2017)
Onyx: A randomized, double-masked, active-controlled phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration. Sponsor: Regeneron
Sub-Investigator (2015-2017)
Phase 2, randomized, double-masked, vehicle-controlled, proof of concept study for topically delivered LHA510 as a maintenance therapy in wet AMD. Sponsor: Alcon
Sub-Investigator (2015-2017)
Capella: a phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age- related macular degeneration. Sponsor: Regeneron.
Sub-Investigator (2015-2017)
Protocol OPH1006: An 18-month phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti- PDGF BB pegylated aptamer). Sponsor: Ophthotech.
Sub-Investigator (2015-2017)
Protocol OPH1005: Phase 2A open label safety study of Fovista (anti-PDGF BB) regimen administered in combination with anti-VEGF therapy to study sub-retinal fibrosis in neovascular AMD. Sponsor: Ophthotech
Sub-Investigator (2014-2017)
Protocol OPH1004: A phase 3 safety and efficacy study of Fovista intravitreous administration in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy. Sponsor: Ophthotech
Sub-Investigator (2014-2017)
ORBIT study: Phase 4 study of intravitreal Jetrea for vitreomacular adhesion. Sponsor: Thrombogenics
Sub-Investigator (2010-2019)
Diabetic Retinopathy Clinical Research Network (DRCR.net). A collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema and associated conditions. Protocols R, V, U, and AC. Sponsor: NEI.
Research Assistant (2002-2004)
Norman P. Blair MD: Ocular Trauma Database. University of Illinois Eye and Ear Infirmary.
Extracurricular
Cure Network. (2010-2018)
Providing the underserved with eye care, glasses.: Medical Director for Ophthalmology (2012)
Professional Societies
Illinois Society of Eye Physicians and Surgeons—2010-Present
American Society of Retina Specialists (FASRS)-Fellow—2010-Present
Fellow of the American College of Surgeons (FACS)—2010-Present
Rabb Retina Society—2006-Present
Chicago Ophthalmological Society—2005-Present
Association for Research in Vision and Ophthalmology—2004-Present
American Academy of Ophthalmology—2004-Present
Board Member, Macular Degeneration Association—2013-Present
Vision Clinic Director, CURE Network, Westchester, Illinois—2011-2012
Member, Foundation for Fighting Blindness—2013-Present
Certification
American board of Ophthalmology—2010